Study guide
3.1 Osmotic Agents
ABIM Neurocritical Care Subspecialty Certification Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Practice Pathway, and the IM Training Route 1.3 Format, Scoring, Pearson VUE, and Score Reports 1.4 How to Use This Independent Study Guide
2 ICU Neurologic Exam, Cerebral Physiology, and CSF
2.1 Neurological Examination in the ICU 2.2 Cerebral Physiology, ICP, CBF, and Autoregulation 2.3 CSF Physiology
3 Core Neuropharmacology
3.1 Osmotic Agents 3.2 Anti-Seizure Drugs 3.3 Anesthetics, Sedatives, Analgesia, and Paralytics 3.4 Antihypertensives, Vasopressors, and Inotropes
4 Reperfusion Drugs, Airway, and Ventilation
4.1 Thrombolytics, Anticoagulants, and Antiplatelets 4.2 Reversal of Anticoagulation After Acute Hemorrhage 4.3 Airway Management and Tracheostomy 4.4 Mechanical Ventilation
5 Hemodynamics and Shock
5.1 Hemodynamic Monitoring 5.2 IABP, Temporary VADs, LVAD, and ECMO 5.3 Diagnosis and Management of Shock
6 Nutrition, Temperature, and ICU Prophylaxis
6.1 Nutrition (01.J) 6.2 Temperature Control (01.K) 6.3 ICU Prophylaxis, Delirium, and Early Mobility (01.L)
7 General Trauma
7.1 Emergency Evaluation of Polytrauma, Chest, and Abdominal Trauma 7.2 Long-Bone Fractures and Fat Embolism 7.3 Burns, Electrical Injury, and Hanging/Strangulation
8 Pulmonary Critical Care
8.1 Pulmonary Physiology and ARDS (01.N.1–2) 8.2 PE, Pneumonia, and Pulmonary Edema (01.N.3, 7–8) 8.3 COPD, Asthma, PAH, and Bronchoscopy Basics (01.N.4–6, 9)
9 Cardiovascular Critical Care
9.1 Cardiovascular Physiology, Stress Cardiomyopathy, ACS, and Valves 9.2 Arrhythmias and Pacing 9.3 Acute Aortic Dissection and Cardiac Ultrasound
10 Renal and Infectious Disease
10.1 AKI, RRT, and Renal Drug Dosing 10.2 Acid-Base and Electrolyte Disorders 10.3 Severe Sepsis, Septic Shock, and Infective Endocarditis 10.4 Antimicrobial Use and Infection in the Immunosuppressed
11 Endocrine and Salt-Water Disorders
11.1 Pituitary Apoplexy, DI, and Panhypopituitarism (01.R.1–4) 11.2 SIADH and Cerebral Salt Wasting (01.R.5–6) 11.3 Thyrotoxicosis, Myxedema, Adrenal Crisis, and Dysglycemia (01.R.7–9)
12 Gastrointestinal Critical Care
12.1 GI Physiology, Acute Abdomen, Bleed, Ileus, and Perforation (01.S.1–5) 12.2 Mesenteric Ischemia and Abdominal Compartment Syndrome (01.S.6–7) 12.3 Fulminant Liver Failure, Cirrhosis Decompensation, and Hepatic Dosing (01.S.8–10)
13 Hematologic Disorders
13.1 Anemia, Transfusion, Thrombocytopenia, Coagulopathy, and DIC (01.T.1–4) 13.2 VTE in the Neuro ICU (01.T.5) 13.3 Chemo/Immune, SCT, CAR-T, Sickle Cell, and TMA (01.T.6–10)
14 Neuroimaging
14.1 CT of Brain and Spine 14.2 MRI and CT/MR Perfusion 14.3 Noninvasive Angiography and Catheter Angiography
15 EEG, EMG, and CSF Analysis
15.1 EEG, Standard and Processed (02.B) 15.2 Basic EMG Interpretation (02.G) 15.3 CSF Analysis (02.H)
16 ICP, TCD, and Multimodality Monitoring
16.1 ICP Monitoring (02.C) 16.2 Transcranial Doppler (02.D) 16.3 Brain-Tissue Oxygen and Multimodality Monitoring (02.E–F)
17 Brain Death and Bedside Procedures
17.1 Brain Death Prerequisites and Clinical Exam (02.I) 17.2 Apnea Testing and Ancillary Studies (02.I) 17.3 Vascular Access, Thoracic Echo, and Lung Ultrasound (02.J–L)
18 Coma, Anoxia, and Intracranial Hypertension
18.1 Coma and Other States of Altered Consciousness (03.A) 18.2 Global Anoxia-Ischemia and Post-Resuscitation Encephalopathy (03.A.1) 18.3 Toxidromes, ICU Delirium, and Hypertensive Encephalopathy (03.A.2–4) 18.4 Intracranial Hypertension as a Disease State (03.B)
19 Acute Ischemic Stroke
19.1 IV Reperfusion Therapy (03.C.3) 19.2 Mechanical Thrombectomy Windows and Imaging Selection (03.C.3) 19.3 Malignant Hemispheric Infarction and Basilar Artery Occlusion (03.C.1–2)
20 Intraparenchymal Hemorrhage
20.1 Intracerebral Hematoma (03.D.1) 20.2 Cerebellar Hematoma (03.D.2) 20.3 Intraventricular Hemorrhage (03.D.3)
21 SAH, CVST, and Spinal Cord Infarction
21.1 Aneurysmal Subarachnoid Hemorrhage (03.E.1) 21.2 Non-Aneurysmal SAH (03.E.2) 21.3 Cerebral Venous Sinus Thrombosis (03.F) 21.4 Spinal Cord Infarction (03.G)
22 Vascular Anomalies and Traumatic Brain Injury
22.1 Unruptured Aneurysm, Cavernoma, AVM, and Dural AVF (03.H) 22.2 Diffuse Axonal Injury and Cerebral Contusions (03.I.1–2) 22.3 Epidural Hematoma, Subdural Hematoma, and Penetrating Injury (03.I.3–4, 7) 22.4 Arterial Dissection and Carotid-Cavernous Fistula (03.I.5–6)
23 Spine, Hydrocephalus, and CNS Infection
23.1 Spinal Cord Injury, Central Cord, and Neurogenic Shock (03.J) 23.2 Unstable Spine Fractures (03.K) 23.3 Hydrocephalus and CSF Diversion (03.L) 23.4 Acute CNS Infections (03.M)
24 Seizures and Neuromuscular Emergencies
24.1 Status Epilepticus and Seizures (03.N) 24.2 Guillain-Barré Syndrome (03.O.1) 24.3 Myasthenic Crisis (03.O.2) 24.4 Motor Neuron Disease, Acute Myopathies, Rhabdomyolysis, and CINM (03.O.3–6)
25 Inflammatory Disease, Neuro-Oncology, and Special Populations
25.1 Fulminant Demyelinating Diseases (03.P) 25.2 Autoimmune Encephalitis and Acute Autonomic Hyperactivity (03.Q–R) 25.3 Neuro-Oncology and Treatment Complications (03.S) 25.4 Pregnancy/Post-Partum, Post-Transplant, and Pediatric Patients (03.T–U)
26 Neurosurgical and Perioperative Complications
26.1 Postoperative Seizures, Hemorrhage, Ischemia, and Hyperperfusion (04.A, C, D, H) 26.2 Infection, CSF Leak, and Pneumocephalus (04.B, E, F) 26.3 Complications of EVD and Lumbar Drain (04.G, I)
27 Ethics, Prognostication, and Organ Donation
27.1 Communication, Decision-Makers, Advance Directives, and DNR (05.A, B, G) 27.2 Uncertainties of Prognostication and the Self-Fulfilling Prophecy (05.C) 27.3 Palliative Care, Withdrawal, Withholding, and Futility (05.D–F) 27.4 Donation After Cardiac Death and Care of the Organ Donor (05.H–I)
3.1 Osmotic Agents
Key Takeaways Explain This Topic AI
Mannitol 0.25–1 g/kg IV through an in-line filter lowers ICP; inspect for crystals, follow the osmolar gap, and replace urine so the patient is not left hypovolemic.
Hypertonic 3% saline is a titratable sodium load that can often be bolused peripherally; 23.4% saline (typically 30 mL) is a central-line herniation rescue because of extreme tonicity.
Prefer hypertonic saline when the patient is hypovolemic or has chronic kidney disease; mannitol’s diuresis may help volume-overloaded heart-failure physiology if MAP is adequate.
Brain Trauma Foundation guidance supports hyperosmolar therapy to treat intracranial hypertension; it is not a standalone, survival-proven silver bullet.
Over-rapid sodium rise, especially from chronic hyponatremia, risks osmotic demyelination; chloride-rich saline commonly causes hyperchloremic metabolic acidosis.
Last updated: September 2026
Hyperosmolar therapy is the pharmacologic rescue you reach for when intracranial pressure (ICP) threatens cerebral perfusion or herniation. This independent ExamFinch chapter covers how mannitol and hypertonic saline (HTS) work, how to dose them, what to monitor, and how to pick one agent over the other in a real neuro ICU. Both drugs pull water from brain tissue across an intact blood–brain barrier (BBB). Neither reverses the primary injury. Neither replaces airway control, head-of-bed elevation, fever treatment, seizure control, cerebrospinal fluid (CSF) drainage, or surgery.
Why osmotic agents matter on this exam
Items rarely ask you to name a brand. They embed a physiologic trap. Mannitol in a dry, hypotensive trauma patient drops cerebral perfusion pressure (CPP) because CPP equals mean arterial pressure minus ICP. A 23.4% saline push through a tenuous hand intravenous line risks catastrophic extravasation. A patient whose sodium has been 118 mEq/L for days can develop osmotic demyelination syndrome (ODS) if you jump sodium into the 140s in one hour. Crystals in a refrigerated mannitol bag delay a herniation bolus if nobody inspects the solution.
Brain Trauma Foundation (BTF) 4th Edition material treats hyperosmolar therapy as a method to lower ICP. A commonly cited treatment threshold is 22 mmHg . BTF does not establish mannitol or HTS as a silver bullet that independently improves survival. Use osmotherapy to protect the brain and buy minutes while you treat the cause.
Mannitol: dose, filter, and crystals
Mannitol is a sugar alcohol, usually as 20% (200 mg/mL) or 25% solution. The usual neurocritical care bolus is 0.25–1 g/kg IV . Many teams use 0.5–1 g/kg for frank herniation and 0.25–0.5 g/kg for milder ICP spikes. Infuse over about 15–30 minutes. A faster push increases the chance of abrupt plasma expansion followed by hypotension as diuresis begins.
Mannitol raises plasma osmolality, draws water from parenchyma, and reduces blood viscosity. The viscosity change can trigger reflex cerebral vasoconstriction and lower cerebral blood volume. ICP typically begins to fall within 15–30 minutes, peaks around 30–60 minutes, and lasts about 2–6 hours. The kidney filters mannitol and does not reabsorb it, so you get an osmotic diuresis. Where BBB is open, mannitol can enter tissue. When plasma osmolality later falls, water can follow into that tissue and produce rebound intracranial hypertension .
Twenty percent mannitol crystallizes when cold. Inspect the bag under light. If crystals are present, warm the bag until they dissolve; do not inject a slurry. Give the dose through an in-line filter (commonly 5 micron). A reliable peripheral intravenous line can carry a 20% bolus in many units, but extravasation still injures tissue. Intraosseous access is an emergency option when no vein is available.
Osmolar gap and volume
Calculated osmolarity (mg/dL glucose and BUN) is approximately 2 × Na + glucose/18 + BUN/2.8 . The osmolar gap is measured osmolality minus that calculated value. Mannitol widens the gap, so the gap tracks remaining drug better than a lone osmolality number. Classic teaching is to hold further mannitol if the gap exceeds about 20 mOsm/kg or if measured osmolality is driven above roughly 320–340 mOsm/kg , because extra doses add renal and hypovolemic harm with diminishing ICP return. Those cutoffs are heuristics. A herniating patient with a gap of 18 is not a reason to withhold a needed bolus if surgery is 20 minutes away; a euvolemic patient with a gap of 25 and ICP 18 is not a reason to give another 1 g/kg out of habit.
Replace urine milliliter for milliliter with isotonic fluid unless the patient is already volume-overloaded. Hypovolemia after mannitol lowers MAP and therefore CPP. Mannitol is a poor choice in hemorrhagic shock, uncontrolled bleeding, or anuria that cannot clear the osmotic load. Acute kidney injury clusters with high cumulative dose, preexisting chronic kidney disease (CKD) , and hypovolemia.
Hypertonic saline: 3% and 23.4%
HTS is sodium chloride above 0.9%, sometimes with acetate or lactate buffers. Neuro ICUs most often use 3% saline for titratable therapy and 23.4% saline as a small-volume herniation rescue.
3% NaCl has an osmolarity of about 1027 mOsm/L. Typical adult boluses are 2–5 mL/kg (often 250 mL) over 10–20 minutes. Continuous infusions often start near 0.5–1 mL/kg/h and are titrated to sodium and ICP. Many hospitals allow peripheral 3% boluses through a large-bore, well-functioning catheter because the volume is limited. Continuous peripheral 3% still risks phlebitis and extravasation, so central access is preferred for a prolonged drip. Recheck the insertion site every time you walk in the room.
23.4% NaCl is about 8 mOsm/mL. The usual adult rescue is 30 mL over 10–20 minutes (some herniation protocols use a shorter push). This concentration is caustic. Give it through a central venous catheter whenever possible. Intraosseous access is an emergency alternative. Peripheral 23.4% risks severe tissue necrosis if it leaks. ICP can fall within minutes. Repeat dosing is limited by the sodium and chloride you just added.
HTS expands intravascular volume rather than causing a brisk diuresis. That is why it is attractive in hypovolemic brain-injured patients who still need preload. Teams often hold serum sodium in the mid-140s to low-150s mEq/L while ICP is labile and avoid driving sodium much above 160 mEq/L without a compelling reason. There is no single universal ICP sodium setpoint. Check sodium frequently during active titration—every 4–6 hours on an infusion, and sooner after 23.4% boluses. Do not chase ever-higher sodium when ICP is already controlled.
Rebound occurs if a high sodium is dropped too quickly: water returns to the brain and ICP climbs. Wean infusions and liberalize free water gradually. Chloride-rich HTS commonly produces hyperchloremic metabolic acidosis , a non-anion-gap acidosis that can affect renal perfusion and hemodynamics. Balanced hypertonic mixtures exist in some centers; 3% and 23.4% NaCl remain chloride loads.
Osmotic demyelination
ODS, including central pontine myelinolysis, follows over-rapid sodium correction. Risk is highest with chronic hyponatremia , alcoholism, malnutrition, and liver disease. In a patient whose sodium has been 118 mEq/L for days, a 23.4% bolus that jumps sodium by 12 mEq/L in an hour can devastate white matter even if the ICP number looks prettier. Acute sodium falls from cerebral salt wasting or mannitol diuresis are not the same physiology as a sodium that has been low all week, but you still avoid cavalier swings. For chronic hyponatremia, keep correction within commonly cited limits of about 8–10 mEq/L in 24 hours unless a herniation crisis forces a more rapid rescue—and even then, stop the rise once the emergency is controlled.
When to prefer saline versus mannitol
Choose from physiology, not from which bag is closer to the door.
- Clinical situation Favored osmotic strategy Why
- Hypovolemia or hypotension HTS Mannitol diuresis drops preload and CPP
- CKD, oliguria, or prior mannitol nephrotoxicity HTS Mannitol accumulates and injures kidneys
Heart failure with volume overload and adequate MAP Mannitol, cautiously Subsequent diuresis may unload the ventricle; HTS adds a lasting sodium and volume load
Cardiogenic shock or pulmonary edema with low MAP Neither as a first move Restore perfusion; osmotherapy without blood pressure harms CPP
No central access, immediate herniation Mannitol 20% or peripheral 3% bolus 23.4% needs central or intraosseous access
Already severely hypernatremic Mannitol or non-sodium ICP measures More NaCl worsens hypernatremia
Hyponatremia with high ICP HTS, with ODS caution if the hypoNa is chronic Treats both problems if you monitor the rate of rise
Anuric end-stage kidney disease Avoid mannitol; HTS only with a dialysis plan Mannitol cannot be cleared
Heart-failure physiology is a frequent discriminator. Both agents initially expand plasma volume . Mannitol then diureses if the kidneys work. A patient with pulmonary edema, adequate MAP, and urine output may tolerate mannitol better than a sustained HTS infusion. A septic or polytrauma patient who is behind on volume will often look worse after mannitol. CKD and oliguria tilt strongly toward HTS because mannitol is filtered and is nephrotoxic when it stagnates.
Doses, onset, and adverse effects
Agent Typical adult dose Onset Duration Major adverse effects
Mannitol 20% 0.25–1 g/kg IV through a filter 15–30 min 2–6 h Hypovolemia, AKI, electrolyte shifts, rebound ICP, crystals
3% NaCl 2–5 mL/kg bolus or infusion Minutes to tens of minutes Hours while sodium remains high Hypernatremia, hyperchloremic acidosis, phlebitis, ODS if Na rises too fast
23.4% NaCl 30 mL IV central Minutes Hours, sodium-dependent Same as 3% plus severe extravasation injury and an abrupt Na jump
Adjuncts in the same ICP algorithm are not osmotic drugs: head-of-bed elevation, neutral neck position to preserve venous outflow, brief hyperventilation as a bridge (avoid PaCO2 below 25 mmHg), adequate sedation, neuromuscular blockade only when the patient is fighting the ventilator, CSF drainage, and decompressive surgery. Do not stack osmotic boluses as a way to postpone a needed hemicraniectomy.
Exam traps
Using mannitol as a default in a hypotensive TBI patient. Omitting the filter or injecting crystallized mannitol. Giving 23.4% through a 22-gauge hand IV. Treating a sodium of 158 mEq/L with another 23.4% bolus because ICP was 25 once an hour ago. Correcting chronic hyponatremia to 140 mEq/L in a single shift. Claiming that osmotherapy has randomized evidence of a large mortality benefit independent of ICP control. BTF-style care uses these drugs to treat intracranial hypertension, not as a survival panacea.